[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 60 of about 60

Advertisement
4. Little L, Stewart CJ: Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. Mod Pathol; 2010 Apr;23(4):611-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It may be difficult to distinguish reactive glandular lesions from adenocarcinoma in situ of the uterine cervix, and although several immunohistochemical markers have established value in this diagnostic setting, none is completely reliable.
  • Therefore, we investigated cyclin D1 staining in a series of 64 cervical biopsy specimens including examples of normal and reactive endocervical epithelium, adenocarcinoma in situ, stratified mucin-producing intraepithelial lesions, and invasive adenocarcinoma.
  • Thirteen specimens also included a component of high-grade cervical squamous intraepithelial neoplasia.
  • In contrast, most cases of adenocarcinoma in situ were completely negative and, therefore, cyclin D1 staining distinguished benign from neoplastic epithelial cells.
  • Although focal cyclin D1 expression was observed in 5/19 cases of adenocarcinoma in situ, the staining was associated with more marked cytological atypia precluding confusion with a reactive process.
  • In conclusion, cyclin D1 can be included within an immunohistochemical panel to aid in the distinction between reactive cervical glandular lesions and adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Cyclin D1 / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20062011.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 136601-57-5 / Cyclin D1
  •  go-up   go-down


5. Maley SN, Schwartz SM, Johnson LG, Malkki M, Du Q, Daling JR, Li SS, Zhao LP, Petersdorf EW, Madeleine MM: Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study. Int J Immunogenet; 2009 Dec;36(6):367-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study.
  • We conducted a population-based case-control study to test the hypothesis that common genetic variation in CXCL12 individual single nucleotide polymorphism (SNP) alleles and haplotypes] is associated with the risk of cervical carcinoma.
  • Cases (n = 917) were residents of western Washington State diagnosed with invasive squamous cell cervical carcinoma (SCC), invasive adenocarcinoma or adenosquamous carcinoma, or adenocarcinoma in situ of the cervix.
  • The minor allele of intronic SNP rs266085 was inversely associated with cervical cancer under a recessive genetic effects model (OR = 0.74, 95% CI: 0.56-0.98).
  • A stepwise procedure identified rs17885289, rs266085 and 3'-untranslated region (UTR) SNP rs266093 as the most parsimonious subset of SNPs necessary to define the haplotype inversely associated with cervical cancer risk in our study.
  • A 3'-UTR SNP, rs1801157, previously found to be related to HIV pathogenesis, was not associated with cervical cancer risk.
  • Further population-based studies are warranted to confirm these associations between genetic variation in CXCL12 and cervical cancer risk.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Mar 1;107(5):1761-7 [16269611.001]
  • [Cites] Tissue Antigens. 2006 Feb;67(2):127-33 [16441483.001]
  • [Cites] Int J Mol Med. 2006 Oct;18(4):785-93 [16964435.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):478-83 [17362322.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):577-86 [17366619.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5056-62 [17785557.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1652-8 [17894551.001]
  • [Cites] Oncol Rep. 2007 Dec;18(6):1583-7 [17982648.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3532-9 [18451182.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1790-9 [18628433.001]
  • [Cites] BMC Genet. 2008;9:90 [19102730.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1117-21 [10613347.001]
  • [Cites] Eur J Neurosci. 2000 Jun;12(6):1857-66 [10886327.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2597-606 [12239174.001]
  • [Cites] Am J Epidemiol. 2003 Feb 1;157(3):218-26 [12543621.001]
  • [Cites] Nat Genet. 2003 May;34(1):70-4 [12692554.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] Biostatistics. 2003 Oct;4(4):513-22 [14557108.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]
  • [Cites] J Med Genet. 2004 May;41(5):e59 [15121787.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):233-45 [15339043.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):829-33 [8752280.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):541-8 [8827359.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1101-9 [9064327.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):381-6 [9833747.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Immunol Rev. 2005 Feb;203:235-43 [15661033.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):493-5 [15686457.001]
  • [Cites] J Infect Dis. 2005 Mar 15;191(6):969-76 [15717274.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1069-75 [15809352.001]
  • [Cites] J Mol Biol. 2005 Apr 22;348(1):43-62 [15808852.001]
  • [Cites] Hum Mol Genet. 2005 Jun 15;14(12):1579-85 [15843397.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):261-6 [15978329.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):311-5 [15955592.001]
  • [Cites] Tissue Antigens. 2005 Oct;66(4):321-4 [16185329.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):276-9 [16249700.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):521-6 [16284526.001]
  • [Cites] Genes Immun. 2005 Dec;6(8):691-8 [16177829.001]
  • [Cites] Gene. 2006 Jun 7;374:174-9 [16626895.001]
  • (PMID = 19788587.001).
  • [ISSN] 1744-313X
  • [Journal-full-title] International journal of immunogenetics
  • [ISO-abbreviation] Int. J. Immunogenet.
  • [Language] ENG
  • [Grant] United States / NHGRI NIH HHS / HG / T32HG00035; United States / NCI NIH HHS / CA / CA112512-02; United States / NCI NIH HHS / CA / R01CA112512; United States / NCI NIH HHS / CA / R01 CA112512-02; United States / NCI NIH HHS / CA / P01 CA042792-219003; United States / NCI NIH HHS / CA / P01CA04279; United States / NCI NIH HHS / CA / R25 CA094880; United States / NCI NIH HHS / CA / CA112512-01; United States / NIEHS NIH HHS / ES / P30ES07033; United States / NHGRI NIH HHS / HG / T32 HG000035; United States / NCI NIH HHS / CA / CA112512-04; United States / NCI NIH HHS / CA / R01 CA112512-01; United States / NCI NIH HHS / CA / R01 CA112512-03; United States / NIEHS NIH HHS / ES / P30 ES007033; United States / NCI NIH HHS / CA / R01 CA112512-04; United States / NCI NIH HHS / CA / R25CA094880; United States / NCI NIH HHS / PC / N01-PC-35412; United States / NCI NIH HHS / CA / CA042792-219003; United States / NCI NIH HHS / CA / P01 CA042792; United States / NCI NIH HHS / CA / CA112512-03; United States / NCI NIH HHS / CA / CA112512-05; United States / NCI NIH HHS / CA / R01 CA112512-05; United States / NCI NIH HHS / CA / R01 CA112512
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12
  • [Other-IDs] NLM/ NIHMS144226; NLM/ PMC2784202
  •  go-up   go-down


6. Sidoruk AA, Novik VI, Urmancheeva AF: [Clinico-morphological diagnosis of adenocarcinoma in situ of the cervix uteri]. Vopr Onkol; 2009;55(6):733-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinico-morphological diagnosis of adenocarcinoma in situ of the cervix uteri].
  • Clinical and morphological investigation involved 57 patients with adenocarcinoma in situ of the cervix uteri (poorly-differentiated (precancerous) cell carcinoma in situ (PAIS)--30; adenocarcinoma in situ (AIS)--27).
  • Predictions for PAIS histotype were confirmed in 83%, cytological findings--78%; AIS--52% and 58%, respectively.
  • Accuracy for PAIS and AIS biopsy was 52% and 32%, respectively.
  • However, our procedure failed to detect malignant process in 17.5% (PAIS--6 cases and AIS--4) which was established by use of smears (Feulgen).
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Vaginal Smears


7. Graesslin O, Dedecker F, Collinet P, Jouve E, Urbaniack D, Leroy JL, Boulanger JC, Quéreux C: [Management of in situ cervical adenocarcinoma]. Gynecol Obstet Fertil; 2006 Dec;34(12):1178-84
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of in situ cervical adenocarcinoma].
  • [Transliterated title] Prise en charge de l'adénocarcinome in situ du col utérin.
  • The management of adenocarcinoma in situ of the cervix (ACIS) is difficult because it is often diagnosed in younger women who may wish to preserve their potential of fertility.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Colposcopy / methods. Reproduction. Uterine Cervical Neoplasms / surgery


8. Young JL, Jazaeri AA, Lachance JA, Stoler MH, Irvin WP, Rice LW, Andersen WA, Modesitt SC: Cervical adenocarcinoma in situ: the predictive value of conization margin status. Am J Obstet Gynecol; 2007 Aug;197(2):195.e1-7; discussion 195.e7-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenocarcinoma in situ: the predictive value of conization margin status.
  • OBJECTIVE: We evaluated the impact of conization margin status on outcomes of patients diagnosed with cervical adenocarcinoma in situ.
  • STUDY DESIGN: A retrospective chart review identified patients at a University hospital from 1988-2006 with adenocarcinoma in situ (AIS) on conization.
  • Of patients with positive margins, 55% (12/22) were diagnosed with residual or recurrent disease, including 3 patients diagnosed with adenocarcinoma on hysterectomy.
  • Thirteen percent of patients with negative conization margins (6/46) were diagnosed with residual or recurrent disease, including 2 patients diagnosed with adenocarcinoma during follow-up.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Cervix Uteri / pathology. Conization. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689647.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Akiba Y, Kubushiro K, Fukuchi T, Fujii T, Tsukazaki K, Mukai M, Nozawa S: Is laser conization adequate for therapeutic excision of adenocarcinoma in situ of the uterine cervix? J Obstet Gynaecol Res; 2005 Jun;31(3):252-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is laser conization adequate for therapeutic excision of adenocarcinoma in situ of the uterine cervix?
  • AIMS: To determine the safety of uterine-preserving operations for adenocarcinoma in situ of the cervix.
  • METHODS: Fifteen cases of adenocarcinoma in situ (AIS) were diagnosed using neodymium:yttrium aluminum garnet (Nd:YAG) laser conization.
  • The accuracy of preconization histology or cytology was evaluated in 15 AIS cases.
  • In these AIS cases, we investigated how far the tumor was located from the squamocolumnar junction (SCJ) and the endocervix.
  • Fourteen cases of the 15 AIS-affected patients were treated using laser conization alone.
  • RESULTS: Precise agreement between preconization diagnosis and conization histology was seen in 46.7% (7/15) of the AIS cases.
  • In 14 of the 15 cases of AIS (93.3%), the tumor was adjacent to the transitional zone, within 3 mm of the SCJ, and in the other case (6.7%), the tumor was between 0 and 5 mm away from the SCJ.
  • None of the 15 patients showed any recurrence of AIS during follow up ranging from 15 to 75 months (43.1 months on average).
  • CONCLUSIONS: Women with AIS who want to preserve their fecundity might be treated with laser conization alone.
  • [MeSH-major] Adenocarcinoma / surgery. Cervix Uteri / surgery. Conization / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916663.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Dedecker F, Graesslin O, Bonneau S, Quéreux C: [Persistence and recurrence of in situ cervical adenocarcinoma after primary treatment. About 121 cases]. Gynecol Obstet Fertil; 2008 Jun;36(6):616-22
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Persistence and recurrence of in situ cervical adenocarcinoma after primary treatment. About 121 cases].
  • [Transliterated title] Persistance et récidive des adénocarcinomes in situ après traitement: à propos d'une série rétrospective multicentrique de 121 cas.
  • OBJECTIVE: The aim of this study is to assess the results of conservative management of adenocarcinoma in situ (AIS) of the uterine cervix.
  • Patients with cervical invasive lesions were excluded.
  • General characteristics of population, diagnosis circumstances, treatment, histology and evolution were studied.
  • DISCUSSION AND CONCLUSION: Conservative surgery for patients with AIS could be considered in young patients but several conditions should be respected: careful follow-up after conservative treatment; cold knife conization; length of cone specimen greater than 25 mm and negative margins.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Neoplasm Recurrence, Local / prevention & control. Papillomavirus Infections / surgery. Uterine Cervical Neoplasms / surgery


14. Bull-Phelps SL, Garner EI, Walsh CS, Gehrig PA, Miller DS, Schorge JO: Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix. Gynecol Oncol; 2007 Nov;107(2):316-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix.
  • OBJECTIVES: Cervical adenocarcinoma in situ (AIS) is a precursor of invasive disease that is increasing in incidence primarily among reproductive-age women of low parity.
  • Conization is an alternative to hysterectomy that allows future pregnancy, but has an inherent risk of residual AIS.
  • METHODS: Women diagnosed with cervical AIS who underwent primary fertility-sparing surgery with either loop excision or cold knife conization between 1993 and 2001 were identified at three institutions.
  • Patients 40 years of age and older and those undergoing hysterectomy within 12 months of diagnosis were excluded.
  • No invasive cervical adenocarcinomas were observed during the study interval.
  • CONCLUSION: Fertility-sparing surgery enables women with cervical AIS to achieve pregnancy with minimal risk of developing invasive disease during surveillance.
  • [MeSH-major] Adenocarcinoma / surgery. Conization. Fertility. Gynecologic Surgical Procedures / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Carcinoma in Situ / surgery. Cohort Studies. Female. Humans. Hysterectomy. Medical Records. Parity. Population Surveillance. Pregnancy. Pregnancy Outcome. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689593.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


15. Griffin D, Manuck TA, Hoffman MS: Adenocarcinoma in situ of the cervix in pregnancy. Gynecol Oncol; 2005 May;97(2):662-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ of the cervix in pregnancy.
  • INTRODUCTION: The number of patients diagnosed with adenocarcinoma in situ of the cervix has increased in the last decade.
  • CASES: In this report, we describe three patients diagnosed with adenocarcinoma in situ of the cervix during pregnancy.
  • DISCUSSION: The management of adenocarcinoma in situ of the cervix may include procedures which present substantial risks to an ongoing pregnancy and more conservative management may be warranted in many instances.
  • [MeSH-major] Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adult. Carcinoma in Situ / diagnosis. Carcinoma in Situ / surgery. Female. Humans. Pregnancy


16. McCluggage WG, Shah R, Connolly LE, McBride HA: Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol; 2008 Jan;27(1):92-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
  • Most cases of cervical adenocarcinoma in situ (AIS) and adenocarcinoma are of the usual or endocervical type.
  • However, intestinal types of AIS and adenocarcinoma exist.
  • With an intestinal-type adenocarcinoma in the cervix, the question may arise as to whether one is dealing with a primary cervical neoplasm or direct or secondary spread from an intestinal adenocarcinoma.
  • In organs such as the ovary, urinary bladder, esophagus, and gallbladder, intestinal-type glandular epithelium often expresses enteric markers, but this has hardly been studied in the cervix.
  • The purpose of this study was to investigate whether intestinal-type AIS and adenocarcinoma in the cervix express enteric markers and to ascertain whether these antibodies are of value in the distinction from a metastatic intestinal adenocarcinoma.
  • We compared the immunophenotype of these lesions with that of usual-type AIS and adenocarcinomain the cervix.
  • Cases included were AIS of usual type (n = 6), primary cervical adenocarcinoma of usual type (n = 6), AIS of intestinal type (n = 21), primary cervical adenocarcinoma of intestinal type (n = 3), primary cervical adenocarcinoma with signet ring cells (n = 2), and colorectal adenocarcinoma involving the cervix (n = 5).
  • Usual-type AIS was always diffusely CK7 positive, typically diffusely CEA and p16 positive, and always CK20 negative.
  • All usual cervical adenocarcinomas were diffusely CK7 and p16 positive, and all were immunoreactive with CEA.
  • Intestinal-type AIS was diffusely CK7 positive (all cases) and typically CK20 negative and diffusely CEA and p16 positive.
  • In addition, usual-type AIS adjacent to intestinal type was CDX2 positive in 13 of 21 cases.
  • The 3 cases of primary cervical intestinal-type adenocarcinoma were diffusely CK7 positive, focally or diffusely positive with CK20 and CDX2, and focally positive with CEA.
  • The foci of signet ring cells in the 2 primary cervical adenocarcinomas were diffusely CK7 and p16 positive and negative with CK20 and CDX2.
  • Colorectal adenocarcinomas involving the cervix were typically diffusely positive with CK20, CEA, and CDX2; negative with CK7; and negative or focally positive with p16.
  • Intestinal types of cervical AIS and adenocarcinoma exhibit a partial enteric immunophenotype, usually with diffuse expression of CDX2 and, in some cases, staining with CK20.
  • Although there is immunophenotypic overlap, focal staining with CK20 together with diffuse CK7 and sometimes p16 positivity helps to distinguish intestinal types of cervical adenocarcinoma from involvement by a colorectal adenocarcinoma; CEA and CDX2 are of no value in this regard.
  • CDX2 positivity in usual-type AIS adjacent to intestinal type and in occasional cases of pure usual-type AIS may be a reflection of early intestinal differentiation before this is morphologically apparent.
  • Using a set of cases of AIS diagnosed in a single institution over a 7-year period (77 usual type; 13 intestinal type), intestinal type was more likely to be associated with early invasive adenocarcinoma than usual type (31% vs 17%), suggesting that intestinal differentiation may be a risk factor for invasion in premalignant cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Intestinal Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / biosynthesis. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156982.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


17. Zafar N, Balazs L, Benstein BD: Synchronous high-grade squamous intraepithelial lesion and adenocarcinoma in situ of cervix in a young woman presenting with hyperchromatic crowded groups in the cervical cytology specimen: report of a case. Diagn Cytopathol; 2008 Nov;36(11):823-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous high-grade squamous intraepithelial lesion and adenocarcinoma in situ of cervix in a young woman presenting with hyperchromatic crowded groups in the cervical cytology specimen: report of a case.
  • We report a 29-year-old woman who underwent routine gynecologic evaluation at a community clinic and had a cervical sample drawn for liquid-based cytologic evaluation.
  • At biopsy, the cervix contained synchronous squamous cell carcinoma in situ, secondarily involving endocervical glands, and neighboring adenocarcinoma in situ.
  • This case re-emphasizes the challenge associated with accurate evaluation of HCG at cytology, the significance of ancillary testing for surrogate markers of high-risk HPV (HR-HPV) infection, the need for adjunct testing for HPV-DNA in the setting of HCG at cervical cytology, and a recommendation to set up studies to evaluate the role of surrogate markers of HR-HPV infection in cytologic samples with HCG.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831021.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Hurrell DP, Jamison J, Dobbs SP, McCluggage WG: Cervical adenocarcinoma in situ recurring as vaginal adenocarcinoma 16 years after hysterectomy. Int J Gynecol Pathol; 2009 May;28(3):296-300
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenocarcinoma in situ recurring as vaginal adenocarcinoma 16 years after hysterectomy.
  • We report a case in which a vaginal adenocarcinoma was discovered in a 67-year-old woman 16 years after hysterectomy for cervical adenocarcinoma in situ.
  • Both the vaginal and cervical lesions exhibited morphologic and immunohistochemical (CDX2-positive) features of intestinal differentiation.
  • Linear array human papillomavirus genotyping demonstrated the vaginal adenocarcinoma to contain human papillomavirus 45.
  • We believe the vaginal adenocarcinoma to be related to the cervical adenocarcinoma in situ and to represent recurrence of this.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / pathology. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620950.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Xu JY, Hashi A, Kondo T, Yuminamochi T, Nara M, Hashi K, Murata S, Katoh R, Hoshi K: Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia. Int J Gynecol Pathol; 2005 Jul;24(3):296-302
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia.
  • The human papillomavirus (HPV) is basically always detected in squamous cell carcinoma of the cervix and its precursors; a high incidence of HPV also has been reported in adenocarcinoma and adenocarcinoma in situ of the uterine cervix.
  • It is difficult to differentiate minimal deviation adenocarcinoma (MDA) from LEGH preoperatively or postoperatively by clinical and pathologic features.
  • As the control, HPV DNA was detected in all cases of squamous cell carcinoma and three of five cases of adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Neoplasms, Glandular and Epithelial / virology. Papillomaviridae / growth & development. Papillomavirus Infections / complications. Tumor Virus Infections / virology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968208.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


20. Dalrymple C, Valmadre S, Cook A, Atkinson K, Carter J, Houghton CR, Russell P: Cold knife versus laser cone biopsy for adenocarcinoma in situ of the cervix--a comparison of management and outcome. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):116-20
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cold knife versus laser cone biopsy for adenocarcinoma in situ of the cervix--a comparison of management and outcome.
  • Eighty-two patients with adenocarcinoma in situ of the cervix managed at Royal Prince Alfred Hospital were reviewed and data were collected on those treated by cold knife cone biopsy (n= 38) and laser cone biopsy (n= 44).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Conization / methods. Laser Therapy. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506846.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Dede M, Gezginç K, Ulubay M, Alanbay I, Güran S, Yenen M: A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer. Eur J Gynaecol Oncol; 2008;29(2):200
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As is known, tamoxifen therapy is related to endometrial proliferation, hyperplasia, polyp formation, invasive carcinoma and uterine sarcoma.
  • Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Aged. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Female. Humans. Middle Aged. Stomach Neoplasms / chemically induced. Uterine Cervical Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459568.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


22. Odashiro AN, Odashiro DN, Nguyen GK: Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology. Diagn Cytopathol; 2006 Feb;34(2):119-23
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology.
  • Three histologically confirmed minimal deviation endometrioid adenocarcinomas (MDEA) of the uterine cervix with cytologic evaluation by cervical scraping were reviewed.
  • The cytologic manifestations of those three cervical MDEAs overlapped, to some extents, with those of a cervical adenocarcinoma in situ and with those of a well-differentiated endometrial adenocarcinoma invading the cervix.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16511847.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Geldenhuys L, Murray ML: Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium. Acta Cytol; 2007 Jan-Feb;51(1):47-50
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium.
  • OBJECTIVE: To investigate the sensitivity and specificity of the Pap smear for detection of adenocarcinoma in situ of the cervix (AIS), endocervical adenocarcinoma (ECAC) and endometrial adenocarcinoma (EAC) as well as the overall specificity of the smear for detection of glandular lesions in general.
  • STUDY DESIGN: Computer records of the laboratory of the QE II Health Sciences Center, Halifax, were searched for patients who had AIS, ECAC or EAC diagnosed on histology between June 1, 1999, and May 31, 2001 and who had had a Pap smear within the preceding year.
  • Computer records were also searched for patients who had a Pap smear result consisting of suspicious or positive for AIS or adenocarcinoma (AC) with subsequent tissue diagnosis during the same time.
  • RESULTS: One hundred percent of patients with AIS, 80% with ECAC and 22% with EAC on histology had positive findings on a Pap smear performed within a year of the histologic diagnosis.
  • One hundred percent of patients with a Pap smear result consisting of suspicious or positive for AIS or AC and follow-up histology had a lesion on histology: 13% AIS, 13% ECAC, 37% EAC, 23% other AC, 10% high grade squamous lesion and 0.3% low grade squamous lesion.
  • It also confirmed the good sensitivity for glandular lesions of the cervix and the poor sensitivity for glandular lesions of the endometrium.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Carcinoma in Situ. Cervical Intraepithelial Neoplasia / diagnosis. Female. Humans. Sensitivity and Specificity. Uterine Hemorrhage / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17328495.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Lacour RA, Garner EI, Molpus KL, Ashfaq R, Schorge JO: Management of cervical adenocarcinoma in situ during pregnancy. Am J Obstet Gynecol; 2005 May;192(5):1449-51
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cervical adenocarcinoma in situ during pregnancy.
  • OBJECTIVE: Adenocarcinoma in situ (AIS) is a precursor of invasive disease that is being more frequently diagnosed during the reproductive years.
  • The purpose of this study was to review our collective experience managing cervical AIS during pregnancy.
  • STUDY DESIGN: Retrospective medical record review of all women diagnosed with AIS during pregnancy from 1995 to 2004 at 3 academic institutions.
  • Five who received a diagnosis in the early second trimester underwent uncomplicated cold knife conization (CKC) at 14 to 19 weeks' gestation.
  • One patient undergoing postpartum CKC required radical hysterectomy for stage IB1 cervical adenocarcinoma.
  • CONCLUSION: Management of cervical AIS during pregnancy by early second trimester CKC is safe for mother and fetus.
  • [MeSH-major] Adenocarcinoma / surgery. Conization. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery


25. Kennedy CM, Peterson LB, Galask RP: Erosive vulvar lichen planus: a cohort at risk for cancer? J Reprod Med; 2008 Oct;53(10):781-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the occurrence of cancer, including vulvovaginal squamous cell carcinoma (SCC), among women after diagnosis of erosive vulvar lichen planus (LP).
  • RESULTS: A diagnosis of cancer was made in 5 women after diagnosis of erosive vulvar LP.
  • Of these, 1 had stage II vulvar SCC after treatment for stage IIB cervical cancer, and 2 with oral LP had subsequent diagnoses of oral or esophageal SCC.
  • The remaining 2 cancer diagnoses included cervical adenocarcinoma in situ and rectal adenocarcinoma.
  • Estimating the risk of SCC among women with vulvar LP is difficult because of the low prevalence of each disorder.

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004404.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 1K23 HD045769
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


26. Daniel A, Barreth D, Schepansky A, Johnson G, Capstick V, Faught W: Histologic and clinical significance of atypical glandular cells on pap smears. Int J Gynaecol Obstet; 2005 Dec;91(3):238-42
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 197(45.2%) patients had a clinically significant diagnosis including 40 with adenocarcinoma in situ (AIS) of the cervix and 48 with endometrial cancer.
  • CONCLUSION: AGC on a Pap smear is frequently associated with a clinically significant diagnosis.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Neoplasms / pathology. Genital Diseases, Female / pathology. Papanicolaou Test. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202416.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Rabelo-Santos SH, Villa LL, Derchain SF, Ferreira S, Sarian LO, Angelo-Andrade LA, do Amaral Westin MC, Zeferino LC: Variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear. Int J Gynecol Pathol; 2006 Oct;25(4):393-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear.
  • Human papillomavirus (HPV) genotypes cannot fully explain the histological diagnosis of women with glandular abnormalities detected by cervical smear.
  • Thus, this study was designed to analyze the distribution of HPV-16 and HPV-18 variants in women referred because of atypical glandular cells and adenocarcinoma in situ in their cervical smears and its association with histological results.
  • Twenty-four women with HPV-16 and 6 with HPV-18, selected from 160 women with cervical smears suggestive of glandular abnormalities, were included.
  • Among the 15 cases associated with the European variant, 14 (93%) presented squamous neoplasia and 1 (7%) invasive adenocarcinoma.
  • Asian-American HPV-16 variants were significantly associated with histological diagnosis of glandular neoplasia alone (odds ratio, 9.3 [1.4-60.2]) or associated with squamous neoplasia (odds ratio, 18.7 [1.5-232.3]).
  • [MeSH-major] Adenocarcinoma / virology. Cervical Intraepithelial Neoplasia / virology. Human papillomavirus 16 / genetics. Human papillomavirus 18 / genetics. Uterine Cervical Neoplasms / virology. Uterine Cervicitis / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990718.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


28. Cohn DE, Morrison CD, Zanagnolo VL, Goist MM, Copeland LJ: Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins. Gynecol Oncol; 2005 Jul;98(1):158-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins.
  • BACKGROUND: Cervical adenocarcinoma in situ is often diagnosed in younger women who may wish to preserve the potential for fertility.
  • Given that the rate of recurrent adenocarcinoma in situ is relatively low and the risk of invasive adenocarcinoma is extremely rare, conservative management in this population after a cone biopsy demonstrates negative margins has been accepted as an appropriate management strategy.
  • This case challenges the concept of conservative management of cervical adenocarcinoma in situ.
  • CASE: A 42-year-old G2P2002 with previously normal annual cervical cytology had a Pap smear demonstrating atypical glandular cells of uncertain significance.
  • A 1.5-cm lesion was noted at the endocervix, and a punch biopsy revealed adenocarcinoma in situ.
  • A large cold knife cone biopsy confirmed cervical adenocarcinoma in situ with negative margins.
  • Definitive therapy for in situ disease with an extrafascial hysterectomy was performed 12 days after conization, and demonstrated stage IB1 cervical adenocarcinoma.
  • CONCLUSION: Conservative management of cervical adenocarcinoma in situ after a cone biopsy with negative margins does not exclude the possibility of concurrent invasive cervical adenocarcinoma.
  • This case challenges the current balance between risk and benefit associated with the conservative management of cervical adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / pathology. Conization. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913738.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Costa S, Negri G, Sideri M, Santini D, Martinelli G, Venturoli S, Pelusi C, Syrjanen S, Syrjanen K, Pelusi G: Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol Oncol; 2007 Jul;106(1):170-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix.
  • OBJECTIVE: The present study assessed (i) the clinical outcome of patients with conservatively treated cervical adenocarcinoma in situ (AIS), (ii) the accuracy of diagnosing AIS by cytology, colposcopy and histology, as well as (iii) the performance of cervical cytology and HPV testing in detection of residual or recurrent disease after conservatively treated AIS.
  • METHODS: A series of 42 consecutive women (mean age 40.5 years; range 27-63 years) underwent conservative (cone) treatment of AIS and were prospectively followed up for a mean of 40 months (median 42 months), using colposcopy, PAP smear, biopsy and HPV testing (with hybrid capture II) repeated at 6-month intervals.
  • Twenty four patients (57.1%) had AIS as a pure lesions and 18 combined with squamous cell lesion (four had invasive SCC).
  • In four patients, an adenocarcinoma (AdCa) stage IA1 was diagnosed during the follow-up.
  • CONCLUSIONS: These results suggest that HR-HPV test in conjunction with cytology offers clear advantages over single cytology in monitoring the women conservatively treated for cervical AIS.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / virology. Papillomavirus Infections / pathology. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Carcinoma in Situ. Conization. DNA, Viral / analysis. Female. Follow-Up Studies. Humans. Middle Aged. Papanicolaou Test. Papillomaviridae / genetics. Predictive Value of Tests. Treatment Outcome. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481701.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


30. Austin RM, Onisko A, Druzdzel MJ: The Pittsburgh Cervical Cancer Screening Model: a risk assessment tool. Arch Pathol Lab Med; 2010 May;134(5):744-50
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Pittsburgh Cervical Cancer Screening Model: a risk assessment tool.
  • CONTEXT: Evaluation of cervical cancer screening has grown increasingly complex with the introduction of human papillomavirus (HPV) vaccination and newer screening technologies approved by the US Food and Drug Administration.
  • OBJECTIVE: To create a unique Pittsburgh Cervical Cancer Screening Model (PCCSM) that quantifies risk for histopathologic cervical precancer (cervical intraepithelial neoplasia [CIN] 2, CIN3, and adenocarcinoma in situ) and cervical cancer in an environment predominantly using newer screening technologies.
  • RESULTS: The PCCSM compares risk quantitatively over time for histopathologically verifiable CIN2, CIN3, adenocarcinoma in situ, and cervical cancer in screened patients for each current cytology result category and for each HPV result.
  • Prior history also alters the CIN2, CIN3, adenocarcinoma in situ, and cervical cancer risk for patients with common current cytology and HPV test results.
  • The PCCSM can also generate negative risk projections, estimating the likelihood of the absence of histopathologic CIN2, CIN3, adenocarcinoma in situ, and cervical cancer in screened patients.
  • CONCLUSIONS: The PCCSM is a dynamic Bayesian network that computes quantitative cervical disease risk estimates for patients undergoing cervical screening.
  • Continuously updatable with current system data, the PCCSM provides a new tool to monitor cervical disease risk in the evolving postvaccination era.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Early Detection of Cancer / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Papanicolaou Test. Papillomavirus Infections / diagnosis. Risk Assessment. Risk Factors. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441506.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Aximu D, Azad A, Ni R, Colgan T, Nanji S: A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol; 2009 Mar;28(2):114-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
  • The histopathologic distinction of cervical adenocarcinoma in situ (AIS) and invasive adenocarcinoma (AC) from some benign endocervical lesions can be challenging.
  • In this immunohistochemical study the utility of the ProEx C reagent in distinguishing AIS and AC from a variety of non-neoplastic glandular lesions was examined.
  • ProEx C immunohistochemical staining was performed on sections from formalin-fixed, paraffin-embedded tissue of 65 cervical tissues including 48 non-neoplastic cervices (normal [n=10], microglandular hyperplasia [n=10], tubal metaplasia [n=11], cervical endometriosis [n=7], reactive endocervix [n=10]) and 17 cervices with glandular malignancy (AIS [n=12] and AC [n=5]).
  • The median and distribution of scores for both prevalence and intensity was compared for AIS versus each of the 5 benign cervical lesions using a Mann-Whitney U test.
  • The median and distribution of prevalence of immunohistochemical staining for AIS was different from all benign mimics, but the intensity of staining for AIS did overlap with some mimics as it was not significantly different from endometriosis, microglandular hyperplasia, and reactive endocervix.
  • ProEx C reagent has potential as an adjunctive testing tool in the histopathologic diagnosis of both AIS and AC, particularly in difficult cases with small biopsies or foci of disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cervical Intraepithelial Neoplasia / diagnosis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Minichromosome Maintenance Complex Component 2. Pilot Projects. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188825.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


32. Smedts F, Ramaekers FC, Hopman AH: The two faces of cervical adenocarcinoma in situ. Int J Gynecol Pathol; 2010 Jul;29(4):378-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The two faces of cervical adenocarcinoma in situ.
  • In order of frequency, cervical intraepithelial neoplasia (CIN), combined adenocarcinoma in situ (AIS)/CIN lesions, and solitary AIS are the most prevalent premalignant lesions of the uterine cervix.
  • As the morphologic distinction of these subtypes is not always straightforward, we performed an immunophenotyping analysis to establish distinguishing profiles for each of these squamous and glandular progenitor lesions of cervical carcinoma.
  • A series of 26 premalignant cervical lesions, comprising 13 cases of AIS, of which 7 represented solitary AIS and 6 were combined with CIN (combined AIS/CIN), as well as 13 solitary high-grade CIN lesions, were immunophenotypically analyzed using antibodies directed against p16, p63, bcl-2, and cytokeratins (CK) 5, 7, 8, 13, 17, 18, and 19.
  • Combined AIS/CIN lesions also expressed the full complement of markers in both the AIS and CIN compartments.
  • However, the expression of p63, bcl-2, CK5, and CK17 was lower in AIS compared with CIN.
  • The solitary AIS lesions could be subdivided into 2 subgroups, 1 expressing the full complement of markers and a second group in which no expression of p63, bcl-2, CK5, and a sporadically CK17 expression was observed.
  • We conclude that 2 phenotypically distinct types of AIS can be identified, that is, AIS with a reserve cell marker phenotype and AIS with an endocervical glandular phenotype.
  • These observations support the view that reserve cells are capable of bidirectional premalignant transformation, that is, into CIN and reserve cell-type AIS, as well as combined AIS/CIN.
  • The endocervical type of AIS is probably a result of the unidirectional transformation of progenitor cells within the glandular cell compartment.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567153.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


33. Dekker AH: Fostering acceptance of human papillomavirus vaccines. J Am Osteopath Assoc; 2006 Mar;106(3 Suppl 1):S14-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivalent prophylactic human papillomavirus (HPV) vaccines currently in the late stages of clinical testing are safe, immunogenic, and efficacious; and phase 3 tests of a quadrivalent vaccine show that it is 100% effective at preventing HPV types 16 and 18-associated cervical intraepithelial neoplasia grades 2 and 3, adenocarcinoma in situ, and cervical cancer through 2 years of postvaccination follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16729556.001).
  • [ISSN] 0098-6151
  • [Journal-full-title] The Journal of the American Osteopathic Association
  • [ISO-abbreviation] J Am Osteopath Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines; 0 / Viral Vaccines
  • [Number-of-references] 18
  •  go-up   go-down


34. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI: Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol; 2005 Mar;105(3):494-500
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplasia associated with atypical glandular cells on cervical cytology.
  • Most women aged younger than 35 years had a squamous abnormality, whereas women aged 35 years or older had a greater diversity of squamous and glandular lesions and accounted for all cases of endometrial cancer, adenocarcinoma in situ, and cervical adenocarcinoma.
  • [MeSH-major] Cervix Uteri / pathology. Uterine Cervical Dysplasia / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Middle Aged. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Obstet Gynecol. 2005 Jun;105(6):1495
  • (PMID = 15738014.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference: 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis; 2007 Oct;11(4):223-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.
  • OBJECTIVE: To provide updated consensus guidelines for the management of women with cervical intraepithelial neoplasia (CIN) or adenocarcinoma in situ (AIS).
  • In the new guidelines, cytological follow-up is the only recommended management option, regardless of whether the colposcopic examination is satisfactory, for women with CIN 1 who have a low-grade referral cervical cytology.
  • Moreover, management recommendations for women with biopsy-confirmed AIS are now included.
  • CONCLUSION: Updated evidenced-based guidelines have been developed for the management of women with CIN or AIS.
  • These guidelines reflect recent changes in our understanding of human papillomavirus-associated diseases of the cervix and the potential impact of treatment on future pregnancies.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma in Situ / therapy. Cervical Intraepithelial Neoplasia / therapy. Electrosurgery. Uterine Cervical Neoplasms / therapy


36. Sláma J, Freitag P, Cibula D, Fischerová D, Janousek M, Pavlista D, Strunová M, Zikán M, Jancárková N: [Glandular premalignant lesions of the uterine cervix]. Ceska Gynekol; 2006 Dec;71(6):446-50
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glandular premalignant lesions of the uterine cervix].
  • OBJECTIVE: Review of diagnostical and therapeutical methods in glandular premalignant lesions of the uterine cervix.
  • RESULTS: The incidence of invasive adenocarcinomas of the uterine cervix is increasing.
  • PAP-smear of AGC-NOS/-NEO or adenocarcinoma in situ (AIS) in combination with typical colposcopic appearance raise a suspicion of glandular lesion.
  • Direct biopsy must be always performed to get definite diagnosis.
  • CONCLUSION: Diagnosis of glandular premalignat lesion of the uterine cervix is more complicated in comparison to spinocellular one, however it is getting more significant due to increasing incidence.


37. Mikami Y, Kiyokawa T, Moriya T, Sasano H: Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining. Histopathology; 2005 Feb;46(2):130-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining.
  • AIMS: To define the phenotypic alteration of the stromal component in association with destructive invasion which is a crucial feature in distinguishing minimal deviation adenocarcinoma (MDA) from benign endocervical glandular lesions.
  • METHODS AND RESULTS: We studied endocervical glandular hyperplasias including non-specific-type (NEGH) (n = 3) and lobular-type (LEGH) (n = 8), and minimal deviation adenocarcinoma (MDA) (n = 11), well-differentiated endocervical adenocarcinoma of usual-type (WDA) (n = 11), and adenocarcinoma in situ (AIS) (n = 6) of the cervix, by double immunostaining for oestrogen receptor (ER) and alpha-smooth muscle actin (alpha-SMA) using peroxidase- and alkaline phosphatase-polymer methods, respectively.
  • AIS was surrounded by ER+/alpha-SMA- stromal cells.
  • All cases of WDA, MDA, and AIS lacked nuclear staining for ER.
  • [MeSH-major] Actins / analysis. Adenocarcinoma / pathology. Cervix Uteri / pathology. Receptors, Estrogen / analysis. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693884.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Receptors, Estrogen
  •  go-up   go-down


38. Biscotti CV, Ray N: Papanicolaou tests associated with cervical mucosal endometriosis: an analysis of cellular features and comparison to endocervical adenocarcinoma in situ. Diagn Cytopathol; 2010 Aug;38(8):551-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papanicolaou tests associated with cervical mucosal endometriosis: an analysis of cellular features and comparison to endocervical adenocarcinoma in situ.
  • Endometrium directly sampled from endocervical mucosal endometriosis can mimic endocervical adenocarcinoma in situ (AIS) in Papanicolaou (Pap) tests.
  • We analyzed a series of Pap tests to investigate the cellular features of mucosal endometriosis and to assess the utility of stroma and apoptotic bodies in the differential diagnosis with AIS.
  • Pap test samples from patients known to have endocervical mucosal endometriosis were compared with samples containing AIS.
  • By comparison, only one (8%) AIS case had endometrial-type stroma.
  • Seven (58%) AIS cases had apoptotic bodies and three (25%) had mitotic figures.
  • These lesional cells almost always include stroma, which is useful in the differential diagnosis with AIS.
  • We identified stroma significantly more often in endometriosis cases (92%) than in AIS cases (8%).
  • In the absence of stroma, AIS should be considered.
  • [MeSH-major] Carcinoma in Situ / pathology. Cervix Uteri / pathology. Endometriosis / pathology. Mucous Membrane / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / pathology. Vaginal Smears / methods


39. Negri G, Romano F, Vittadello F, Kasal A, Mazzoleni G, Colombetti V, Egarter-Vigl E: Laminin-5 gamma2 chain immunohistochemistry facilitates the assessment of invasiveness and improves the diagnostic reproducibility of glandular lesions of the cervix uteri. Hum Pathol; 2006 Jun;37(6):704-10
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laminin-5 gamma2 chain immunohistochemistry facilitates the assessment of invasiveness and improves the diagnostic reproducibility of glandular lesions of the cervix uteri.
  • The aim of this study was to evaluate the influence of laminin-5 (LN-5) gamma2 chain immunohistochemistry on the assessment of invasiveness in cervical adenocarcinomas and its impact on the diagnostic reproducibility of glandular lesions of the cervix uteri.
  • Immunohistochemistry with LN-5 gamma2 was performed on 30 cases, including 12 adenocarcinomas in situ (AISs), 5 AISs that were suggestive, albeit not conclusive, of infiltration (AIS+), 7 frankly invasive adenocarcinomas, and 6 nonneoplastic cases with reactive changes.
  • Laminin-5 gamma2 was expressed in 5 of the 12 AISs (41.6%), all AIS+ and invasive adenocarcinomas, and none of the reactive cases.
  • The difference in interobserver agreement further increased when including only AISs and AIS+ in the analysis (0.17 versus 0.72; P = .000).
  • After immunohistochemical evaluation, the original AIS diagnosis was unanimously changed to adenocarcinoma with minimal stromal invasion in 3 of 12 cases (25%), whereas a discordant hematoxylin-eosin diagnosis turned into a concordant one in 10 of 13 cases (6 AISs, 2 AIS+, 2 adenocarcinomas; 76.9%).
  • Immunohistochemistry with LN-5 gamma2 facilitates the assessment of the invasiveness of cervical adenocarcinomas and improves the interobserver agreement in glandular lesions of the cervix uteri.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Adhesion Molecules / analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


40. Chang MC, Nevadunsky NS, Viswanathan AN, Crum CP, Feltmate CM: Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. Int J Gynecol Pathol; 2010 Jan;29(1):88-92
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival.
  • Adenocarcinoma in situ (AIS) of the endocervix is typically confined to the cervix, but may be extensive.
  • We report 2 cases of extensive AIS-one with intraendometrial spread-that recurred after cone biopsy and were associated with ovarian metastases.
  • Extensive, recurring AIS is a rare variant that may be unique for its risk of coincident ovarian involvement.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma in Situ / pathology. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 May;29(3):298-300; author reply 300-1; discussion 300-2 [20407334.001]
  • [CommentIn] Int J Gynecol Pathol. 2011 Jan;30(1):62-3 [21131831.001]
  • (PMID = 19952931.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Liang J, Mittal KR, Wei JJ, Yee H, Chiriboga L, Shukla P: Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions. Int J Gynecol Pathol; 2007 Jan;26(1):71-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions.
  • Early detection of premalignant and malignant glandular lesions of the uterine cervix and their distinction from benign mimics is crucial but sometimes difficult.
  • In this study, we investigated utility of expression of p16, CEA, Ki67, p53 and ER/PR in evaluating the benign, premalignant, and malignant glandular lesions of the uterine cervix.
  • A total of 35 cervical cone or LEEP cases were collected including 14 adenocarcinoma in situ (AIS), 7 endocervical glandular dysplasia (EGD), and 14 benign mimics (BM).
  • The histological scores assigned independently by 4 pathologists were all equal or above 6 for AIS, between 3 and 5 for EGD, and equal or below 3 for BM.
  • There was increased expression of p16 and CEA in EGD compared with BM (P < 0.05), with further increase in expression of these markers in AIS compared with EGD (P < 0.05).
  • Ki67 expression was significantly increased in AIS compared to EGD (P < 0.05) as well as compared to BM (P < 0.05).
  • There was a loss of ER/PR in cervical AIS, but not in EGD.
  • Our results indicate that the Silverberg scoring system is a useful tool in differential diagnosis of cervical glandular lesions for increased diagnostic accuracy and interobserver agreement.
  • Most cervical glandular lesions can be differentiated by using a combination of histological scores with a panel of immunomarkers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Carcinoembryonic Antigen / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Diagnosis, Differential. Female. Humans. Ki-67 Antigen / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / metabolism


42. Altaf FJ: Cervical cancer screening with pattern of pap smear. Review of multicenter studies. Saudi Med J; 2006 Oct;27(10):1498-502
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer screening with pattern of pap smear. Review of multicenter studies.
  • OBJECTIVE: To estimate the frequency of abnormal cervical smears and to compare the findings with earlier reported data from Saudi Arabia.
  • The malignant categories were squamous cell carcinoma (0.08%), adenocarcinoma of cervix in situ (0.02%) and invasive (0.04%).
  • Unified national programs for diagnosing cervical precancerous lesions should be established covering different region of the Kingdom to evaluate the magnitude of the problem.
  • [MeSH-major] Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / epidemiology. Vaginal Smears / trends


43. Baker AC, Eltoum I, Curry RO, Stockard CR, Manne U, Grizzle WE, Chhieng D: Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch Pathol Lab Med; 2006 Oct;130(10):1510-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix.
  • OBJECTIVE: To determine the expression of mucins in uterine cervical glandular lesions and whether mucin expression correlates with the nature and origin of the glandular lesions.
  • DESIGN: Antibodies to MUC1, MUC2, MUC4, and MUC5AC were applied on 52 cases including 14 endocervical adenocarcinomas (including 4 adenosquamous carcinomas), 9 endometrial carcinomas (8 endometrioid adenocarcinomas and 1 adenosquamous carcinoma), 8 adenocarcinoma in situ (AIS), 2 glandular dysplasias, 6 tubal metaplasias, 10 microglandular hyperplasias, and 3 normal endocervix.
  • Almost all endocervical AIS and carcinomas and all endometrial adenocarcinomas expressed MUC1; the exceptions were 2 cases of endocervical adenocarcinoma and 1 case of adenosquamous carcinoma of the endocervix.
  • MUC2 staining was noted in 25%, 40%, and 22% of AIS, endocervical adenocarcinomas, and endometrial adenocarcinomas, respectively.
  • About 38% of AIS, 75% of endocervical adenocarcinomas, and 44% of endometrial adenocarcinomas expressed MUC4.
  • Half of AIS, most of endocervical adenocarcinomas, and 22% of endometrial adenocarcinomas expressed MUC5AC.
  • The difference in MUC4 and MUC5AC expression between benign endocervical lesions and AIS and the difference in MUC5AC expression between endocervical and endometrial neoplasms were statistically significant.
  • CONCLUSIONS: Mucin expressions differed among benign endocervical lesions and AIS and among endocervical and endometrial malignancies.
  • These results suggest that mucin staining may potentially be helpful in differentiating various uterine cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Mucins / metabolism. Uterine Cervical Diseases / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090193.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC4 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


44. Salani R, Puri I, Bristow RE: Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol; 2009 Feb;200(2):182.e1-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status.
  • OBJECTIVE: We sought to determine the value of conization margin status in predicting residual and recurrent adenocarcinoma in situ (ACIS) of the cervix.
  • Invasive adenocarcinoma was more commonly associated with positive margins (5.2%) compared with negative margins (0.1%).
  • CONCLUSION: After conization for ACIS, patients with positive margins are significantly more likely to have residual or recurrent disease, whereas those with negative margins may be treated conservatively.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Conization. Neoplasm Recurrence, Local / epidemiology. Neoplasm, Residual / epidemiology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cervix Uteri / pathology. Female. Humans. Predictive Value of Tests. Reoperation

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019325.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


45. Dalla Nora LC, Azara CZ, Pace EL, Martins CM, Zeferino LC, Westin MC, Derchain SF, Rabelo-Santos SH: Cytomorphological criteria, subclassifications of endocervical glandular cell abnormalities, and histopathological outcome: a frequency study. Diagn Cytopathol; 2010 Nov;38(11):806-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to evaluate the frequency and the significance of cytomorphological criteria defined in studies as being predictive of neoplasia in cervical smears of women with a cytological diagnosis of atypical glandular cells (AGC) or adenocarcinoma in situ (AIS).
  • Women (n = 103) with cytological findings suggestive of AGC or AIS, whose diagnoses were later established by histopathology, were included in the study.
  • The criteria analyzed and classified as present or absent in cervical smears previously classified as AGC-NOS (not otherwise specified), AGC-FN (favor neoplasia), or AIS were as follows: irregular nuclear membranes; scanty cytoplasm; dyskeratotic cells; increased nuclear/cytoplasmic ratio; nucleoli; overlapping; papillary clusters, feathering; loss of polarity; nuclear enlargement; coarsely granular chromatin; and pseudostratified strips.
  • Coarsely granular chromatin was observed in 62.5% of cases with a diagnosis of neoplasia.
  • Feathering was present in 80% of cases of histopathological AIS.
  • Loss of polarity and coarsely granular chromatin were significantly associated with neoplastic diagnosis considering all subcategories of glandular abnormalities diagnosis.
  • In AGC-SOE subclassification, coarsely granular chromatin was significantly associated with neoplastic diagnosis.
  • The presence of nucleoli was significantly associated with neoplastic diagnosis in cervical smears qualified as AGC-FN and AIS.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


46. Massad LS, Xie X, Darragh TM, Minkoff H, Levine AM, D'Souza G, Cajigas A, Colie C, Watts DH, Strickler HD: Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus. Obstet Gynecol; 2009 Nov;114(5):1063-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus.
  • OBJECTIVE: To estimate the frequency and histologic correlates of glandular abnormalities in cervical cytology among women with the human immunodeficiency virus (HIV) and to compare findings with those of women without HIV.
  • Glandular abnormalities, including atypical glandular cells (AGC), adenocarcinoma in situ (AIS), and adenocarcinoma, were identified and correlated with biopsy histology.
  • After index abnormal tests, endocervical curettings were obtained from 106 (43%) women, cervical biopsies from 76 (38%), and endometrial biopsies from 19 (8%).

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Int J STD AIDS. 2006 Dec;17(12):831-4 [17212861.001]
  • [Cites] Obstet Gynecol. 2006 Mar;107(3):701-8 [16507944.001]
  • [Cites] J Low Genit Tract Dis. 2007 Oct;11(4):201-22 [17917566.001]
  • [Cites] Obstet Gynecol. 2008 Jun;111(6):1388-93 [18515523.001]
  • [Cites] Am J Obstet Gynecol. 2007 Dec;197(6):566-71 [18060938.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Cancer. 2009 Feb 1;115(3):524-30 [19127538.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):577-86 [15840880.001]
  • [Cites] Clin Diagn Lab Immunol. 2005 Sep;12(9):1013-9 [16148165.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):247-52 [10770344.001]
  • [Cites] AIDS. 2000 Aug 18;14(12):1775-84 [10985315.001]
  • [Cites] Sex Transm Infect. 2000 Aug;76(4):257-61 [11026879.001]
  • [Cites] Biometrics. 1988 Dec;44(4):1049-60 [3233245.001]
  • [Cites] JAMA. 1994 Jun 15;271(23):1866-9 [8196145.001]
  • [Cites] Epidemiology. 1998 Mar;9(2):117-25 [9504278.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] Int J Cancer. 1999 Jul 30;82(3):334-7 [10399949.001]
  • (PMID = 20168108.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / UO1-HD-32632; United States / NIAID NIH HHS / AI / UO1-AI-34994; United States / NIAID NIH HHS / AI / UO1-AI-34989; United States / NIAID NIH HHS / AI / U01 AI031834; United States / NIAID NIH HHS / AI / U01 AI035004; United States / NCRR NIH HHS / RR / UL1 RR024131; United States / NIAID NIH HHS / AI / U01 AI034989; United States / NIAID NIH HHS / AI / UO1-AI-35004; United States / NIAID NIH HHS / AI / UO1-AI-34993; United States / NIAID NIH HHS / AI / U01 AI034994; United States / NIAID NIH HHS / AI / U01 AI035004-08S1; United States / NCI NIH HHS / CA / R01-CA-085178; United States / NIAID NIH HHS / AI / AI035004-08S1; United States / NIAID NIH HHS / AI / UO1-AI-42590; United States / NCI NIH HHS / CA / R01 CA085178; United States / NIAID NIH HHS / AI / U01 AI034993; United States / NIAID NIH HHS / AI / UO1-AI-31834; United States / NICHD NIH HHS / HD / U01 HD032632; United States / NIAID NIH HHS / AI / U01 AI042590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS257741; NLM/ PMC3032588
  •  go-up   go-down


47. Chen L, Yang B: Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. Cancer; 2008 Aug 25;114(4):236-41
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology.
  • BACKGROUND: Reflex human papillomavirus (HPV) testing for atypical squamous cells of undetermined significance (ASC-US) has improved the sensitivity and specificity in detecting high-grade squamous dysplasia (cervical intraepithelial neoplasia [CIN]2+).
  • This report is of a 5-year experience with reflex HPV testing in women with AEC and assessment of the potential role of reflex HPV testing in guiding subsequent colposcopy-directed cervical biopsy/curettage in a large tertiary care hospital setting.
  • The most severe histopathologic diagnosis was recorded.
  • Histopathologic examination of the 64 HPV-positive AEC cases revealed 18 cases of endocervical adenocarcinoma in situ/adenocarcinoma (AIS+) and 22 cases of CIN2+.
  • Among 253 of the HPV-negative AEC women, AIS+ was found in only 3 cases and CIN2+ in 1 case.
  • Cervical AIS+ was found in 28% of the HPV-positive AEC patients and in only 0.9% of the HPV-negative patients (P<.0001).
  • When the significant glandular (AIS+) and squamous (CIN2+) lesions were combined, 62.5% of the lesions were detected in HPV-positive AEC cases compared with 1.6% in the HPV-negative AEC cases (P<.0001).
  • CONCLUSIONS: Because of a high sensitivity (91.0%) and high specificity (91.2%) in detecting significant cervical lesions, reflex HPV testing for cytologic diagnosis of AEC appears to be a useful ancillary tool in the selection of high-risk patients for colposcopy.
  • [MeSH-major] Cervix Uteri / pathology. DNA, Viral / analysis. Papanicolaou Test. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Retrospective Studies. Sensitivity and Specificity


48. FUTURE II Study Group: Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis; 2007 Nov 15;196(10):1438-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18 in 16-26-year-old women naive for HPV vaccine types.
  • RESULTS: Vaccination was 100% effective (95% confidence interval [CI], 79%-100%) in preventing incident cervical intraepithelial neoplasia 2 or 3 or cervical adenocarcinoma in situ caused by the HPV type or types for which the women were negative at enrollment.
  • [MeSH-minor] Adolescent. Adult. Antibodies, Viral / blood. Cervical Intraepithelial Neoplasia / prevention & control. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / analysis. Double-Blind Method. Enzyme-Linked Immunosorbent Assay. Female. Humans. Injections, Intramuscular. Polymerase Chain Reaction. Prospective Studies. Treatment Outcome. Uterine Cervical Neoplasms / prevention & control. Uterine Cervical Neoplasms / virology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Infect Dis. 2007 Nov 15;196(10):1431-2 [18008218.001]
  • (PMID = 18008221.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Papillomavirus Vaccines
  •  go-up   go-down


49. El-Ghobashy AA, Shaaban AM, Innes J, Prime W, Herrington CS: Differential expression of cyclin-dependent kinase inhibitors and apoptosis-related proteins in endocervical lesions. Eur J Cancer; 2007 Sep;43(13):2011-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, a panel of cyclin-dependent kinase inhibitors (CDKIs) and apoptosis-related proteins (p16, p21, p53, Bcl2 and hsp27) was analysed by immunohistochemistry in 91 glandular cervical lesions.
  • A significant increase in p21 and p53 expression occurred from normal cervix (n=11) through endometriosis/tubo-endometrioid metaplasia (TEM) (n=19) and cervical glandular intraepithelial neoplasia (CGIN)/adenocarcinoma in situ (AIS) (n=33) to invasive adenocarcinoma (n=28).
  • p16 showed diffuse strong expression in CGIN/AIS and invasive adenocarcinoma compared with focal expression in some TEM/endometriosis lesions and no expression in normal cervix.
  • Bcl2 was highly expressed in TEM/endometriosis compared with CGIN/AIS and adenocarcinoma. p16 immunostaining discriminated accurately between neoplastic and non-neoplastic cervical lesions, provided that diffuse strong positivity was present.
  • Similarly, diffuse expression of Bcl2 distinguished endometriosis/TEM from CGIN/AIS.
  • These data demonstrate that analysis of CDKIs and apoptosis-related proteins provides useful information in the diagnostic assessment of glandular lesions of the cervix.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Cyclin-Dependent Kinase Inhibitor Proteins / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693084.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor Proteins
  •  go-up   go-down


50. Roberts JM, Thurloe JK, Biro C, Hyne SG, Williams KE, Bowditch RC: Follow-up of cytologic predictions of endocervical glandular abnormalities: histologic outcomes in 123 cases. J Low Genit Tract Dis; 2005 Apr;9(2):71-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We obtained histologic follow-up for 100% of 67 cytologic predictions of adenocarcinoma in situ (AIS) and 82% of 39 predictions of possible AIS (?AIS) made over a 4-year period (1999-2002) and for 25% of 105 atypical endocervical cells (AEC) predictions over a 12-month period (2000).
  • RESULTS: PPVs for predictions of AIS and ?AIS for high-grade lesions overall were 91% and 75% (p = .032), respectively, and those for high-grade glandular lesions were 88% and 72% (p = .046), respectively.
  • CONCLUSION: Cytology can accurately predict AIS.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cervix Uteri / pathology. Cytodiagnosis / methods. Cytodiagnosis / standards. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Vaginal Smears


51. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the potential use of MGB in gynecologic pathology practice, we tested MGB expression by immunohistochemistry on 47 endocervical adenocarcinomas (whole tissue sections of 13 invasive and 35 in situ) and 55 endometrial carcinomas (39 endometrioid and 16 nonendometrioid represented on a single tissue microarray).
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • Frequent MGB expression in endometrioid endometrial adenocarcinoma is significantly different from nonendometrioid carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


52. van de Nieuwenhof HP, Massuger LF, de Hullu JA, van Ham MA, van Dijck JA, Siebers AG, Bekkers RL: Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003. Br J Cancer; 2008 Jan 15;98(1):165-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003.
  • Over the period 1989-2003, the incidence of cervical adenocarcinoma (n=1615) was stable whereas that of cervical adenocarcinoma in situ (n=1884) significantly decreased (P=0.008), mainly caused by adenocarcinoma in situ lesions with a concurrent squamous dysplasia.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Cell Oncol. 2007;29(1):19-24 [17429138.001]
  • [Cites] CMAJ. 2001 Apr 17;164(8):1151-2 [11338801.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1490-3 [11377601.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):314-26 [12352181.001]
  • [Cites] Cancer. 2002 Dec 25;96(6):330-7 [12478680.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):886-90 [12942122.001]
  • [Cites] Obstet Gynecol. 2003 Oct;102(4):765-73 [14551007.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):336-41 [14681940.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1035-44 [14983500.001]
  • [Cites] J Clin Pathol. 1986 Jan;39(1):22-8 [3950029.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):246-9 [2298414.001]
  • [Cites] Obstet Gynecol. 1995 Jun;85(6):1017-21 [7770247.001]
  • [Cites] Int J Epidemiol. 1996 Apr;25(2):252-8 [9119549.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):166-70 [8995568.001]
  • [Cites] Int J Gynecol Pathol. 1997 Apr;16(2):103-10 [9100062.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):448-52 [9277660.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Obstet Gynecol. 1998 Jun;91(6):969-72 [9611006.001]
  • [Cites] Am J Clin Pathol. 1998 Aug;110(2):200-9 [9704619.001]
  • [Cites] J Clin Pathol. 1999 Feb;52(2):112-7 [10396238.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):159-66 [10487628.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):55-61 [10502426.001]
  • [Cites] Cancer Detect Prev. 2004;28(6):461-4 [15582270.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):1005-9 [15515017.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):376-8 [16012518.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9 [16172231.001]
  • [Cites] Int J Gynecol Pathol. 2005 Oct;24(4):399-403 [16175089.001]
  • [Cites] Acta Obstet Gynecol Scand. 2006;85(1):106-11 [16521689.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):362-7 [17072843.001]
  • [Cites] J Reprod Med. 2000 Aug;45(8):613-5 [10986677.001]
  • (PMID = 18182979.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359688
  •  go-up   go-down


53. Saqi A, Gupta PK, Erroll M, Babiac A, Blackmun D, Mansukhani M, Vazquez M: High-risk human papillomavirus DNA testing: a marker for atypical glandular cells. Diagn Cytopathol; 2006 Mar;34(3):235-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cervical/endocervical cytology screening has decreased morbidity and mortality, and implementing adjunctive human papilloma virus (HPV) DNA testing for atypical squamous cells of undetermined significance has improved the specificity for detecting premalignant squamous lesions.
  • Currently, there are no guidelines to perform HPV DNA testing on cervical/endocervical ThinPreps with atypical glandular cells (AGC).
  • To assess the potential role of HPV DNA testing on AGC cases, Hybrid Capture 2 (Digene Corp.) testing was performed on 144 cervical/endocervical AGC specimens.
  • Of 43 HPV-positive patients, 37 had adenocarcinoma in situ (AIS), atypical squamous cells of undetermined significance (ASCUS), or cervical squamous intraepithelial neoplasia, while only one patient without high-risk HPV had a squamous intraepithelial neoplasia.
  • Furthermore, most high-risk HPV positive AGC cases harbored high-grade squamous intraepithelial lesion (HSIL) rather than AIS.
  • Our data support HPV DNA testing of all AGC specimens to detect cervical, especially squamous, neoplasia.
  • [MeSH-major] Cervix Uteri / virology. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. DNA Probes, HPV. Female. Genetic Markers. Humans. Neoplasms, Squamous Cell / chemistry. Neoplasms, Squamous Cell / diagnosis. Neoplasms, Squamous Cell / pathology. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16470857.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral; 0 / Genetic Markers
  •  go-up   go-down


54. Confortini M, Di Bonito L, Carozzi F, Ghiringhello B, Montanari G, Parisio F, Prandi S, GISCi Working Group for Cervical Cytology: Interlaboratory reproducibility of atypical glandular cells of undetermined significance: a national survey. Cytopathology; 2006 Dec;17(6):353-60
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A set of 35 selected slides were circulated among 167 laboratories involved in local population-based cervical screening programmes.
  • Each laboratory provided one single diagnosis per smear.
  • The smears were read blind to the original diagnosis and to the diagnoses provided by other laboratories.
  • A 'majority' diagnosis was defined for each case and assumed as the reference standard.
  • The diagnosis provided from each laboratory was compared with the majority diagnosis.
  • RESULTS: According to the majority report the 35 slides in the set were classified as negative in nine cases, AGC in eight, adenocarcinoma in eight, and squamous lesion or squamous + glandular lesion in 10.
  • K-values were 0.46, 0.21, 0.34, 0.36 and 0.32 for negative, AGC/AIS (adenocarcinoma in situ of endocervix), AdenoCa, Sq/Sq + Gl and all reporting categories respectively.
  • The data confirmed the importance, in a screening scenario, of AGC/AIS diagnoses, but also presented difficulties in differentiating between the two diagnoses.
  • In addition to the results obtained from the circulation of the slides, laboratories which had annually a low number of cervical smears were able to gain experience focused on particular morphological pictures.
  • [MeSH-major] Cervix Uteri / cytology. Mass Screening / methods. Vaginal Smears / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Humans. Reproducibility of Results. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


55. Tsuda H, Mikami Y, Kaku T, Hasegawa T, Akiyama F, Ohishi Y, Sasajima Y, Kasamatsu T: Reproducible and clinically meaningful differential diagnosis is possible between lobular endocervical glandular hyperplasia and 'adenoma malignum' based on common histopathological criteria. Pathol Int; 2005 Jul;55(7):412-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproducible and clinically meaningful differential diagnosis is possible between lobular endocervical glandular hyperplasia and 'adenoma malignum' based on common histopathological criteria.
  • The aim of the present study was to determine if the differential diagnosis between lobular endocervical glandular hyperplasia (LEGH) and minimal deviation adenocarcinoma (MDA), or 'adenoma malignum', is reproducible when clear criteria for these two lesions are given.
  • A total of 44 proliferative endocervical glandular lesions were collected, for which differential diagnosis from MDA was considered to be necessary.
  • Seven observers independently classified these 44 lesions into LEGH, LEGH with adenocarcinoma in situ (AIS), MDA, or common cervical adenocarcinoma, according to the following criteria: LEGH was non-invasive proliferation of endocervical glandular cells without any obvious adenocarcinoma component.
  • MDA was very well-differentiated endocervical-type mucinous adenocarcinoma composed mostly of LEGH-looking glands but containing the component of obviously invasive adenocarcinoma.
  • LEGH with AIS was defined as continuous coexistence of LEGH and AIS.
  • The level increased to almost perfect (kappa = 0.928) between the group of non-invasive lesions consisting of LEGH and LEGH with AIS and the other group of invasive lesions comprising MDA and common adenocarcinoma.
  • When the modal diagnosis was adopted as the final diagnosis for individual lesions, the 5 year survival rate of patients after surgery was 100% for the non-invasive lesions but only 54% for the invasive lesions (P < 0.01).
  • It is clearly shown that reproducible differential diagnosis is possible between LEGH, LEGH with AIS, and MDA and that such a differentiation is clinically meaningful.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry / methods. Humans. Hyperplasia. Prognosis. Reproducibility of Results. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982216.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


56. Flannelly G: The management of women with abnormal cervical cytology in pregnancy. Best Pract Res Clin Obstet Gynaecol; 2010 Feb;24(1):51-60
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of women with abnormal cervical cytology in pregnancy.
  • The emphasis should be on diagnosis and confirmation of cervical precancer (Cervical intraepithelial neoplasia (CIN) or Adenocarcinoma in situ (AIS), thus excluding invasive cancer).
  • This must include colposcopy and take into account the physiological changes of the cervix during pregnancy and the puerperium.
  • The management of women with invasive cancer diagnosed during pregnancy depends on the gestation at diagnosis and requires careful assessment and multidisciplinary planning.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / surgery. Precancerous Conditions / surgery. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / surgery. Colposcopy. Evidence-Based Medicine. Female. Humans. Hysterectomy / methods. Pregnancy. Survival Analysis. Treatment Outcome. Vaginal Smears

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805007.001).
  • [ISSN] 1532-1932
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


57. Quint KD, de Koning MN, van Doorn LJ, Quint WG, Pirog EC: HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol; 2010 May;117(2):297-301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix.
  • OBJECTIVE: The objective of the study was to compare the distribution of HPV genotypes and HPV16 variants in glandular and squamous cervical neoplasia.
  • METHODS: Cases of endocervical adenocarcinoma in-situ (AIS, n=33) invasive adenocarcinoma (ADCA, n=55), cervical intraepithelial neoplasia-3 (CIN3, n=130) and squamous cell carcinoma (SCC, n=60) were collected at the New York Hospital and tested for HPV using SPF(10)PCR-LIPA(25) (version 1) assays and for HPV16 variants using a multiplex PCR and reverse hybridization assay.
  • RESULTS: There was a difference between the spectrum of HPV genotypes detected in glandular and squamous neoplasia: 13 different HPV genotypes were detected in CIN3 as single infections and 11 in SCC, while only 4 single genotypes were detected in AIS and 3 in ADCA.
  • In AIS, HPV16, 18, 45 and 35 accounted for 69.7%, 27.2%, 3%, 3% of cases.
  • European variants of HPV16 were the most common in CIN3 (83.8%), SCC (71.4%) and AIS (73.9%).
  • AA variant was also detected in 17.4%, 4.1%, and 2.4% of HPV16 positive AIS, CIN3 and SCC, respectively.
  • CONCLUSION: Asian American variant of HPV16, HPV18 and HPV45 are preferentially associated with cervical adenocarcinoma as compared to squamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. Human papillomavirus 16 / genetics. Papillomaviridae / genetics. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / virology


58. Tarkkanen J, Auvinen E, Nieminen P, Malmi R, Vartiainen J, Timonen T, Laurila P, Räisänen I, Unnerus HA, Sakki A, Mattila P, Van Den Brule AV, Tapper AM: HPV DNA testing as an adjunct in the management of patients with low grade cytological lesions in Finland. Acta Obstet Gynecol Scand; 2007;86(3):367-72
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 5/97 (5.2%) high grade lesions, which were HC2-negative but pap-positive, including 1 cervical adenocarcinoma in situ.
  • One CIN3 and one AIS remained HPV negative.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364315.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


59. Fambrini M, Pieralli A, Taddei GL, Penna C: Laser cylindrical excision for cervical adenocarcinoma in situ. Int J Gynaecol Obstet; 2006 Dec;95(3):292-3
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laser cylindrical excision for cervical adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Conization / methods. Laser Therapy / methods. Neoplasm Recurrence, Local. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999959.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


60. Modem RR, Otis CN, Florence RR, Pantanowitz L: Intestinal type adenocarcinoma in situ of the cervix. Diagn Cytopathol; 2007 Sep;35(9):584-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal type adenocarcinoma in situ of the cervix.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Intestinal Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cytological Techniques. Diagnosis, Differential. Female. Humans. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17703459.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement